应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
QGEN 快而精医药
盘前交易 12-15 07:04:56 EST
45.22
-0.22
-0.48%
盘前
45.14
-0.08
-0.18%
04:43 EST
最高
45.30
最低
44.82
成交量
97.72万
今开
45.03
昨收
45.44
日振幅
1.06%
总市值
98.06亿
流通市值
97.12亿
总股本
2.17亿
成交额
4,407万
换手率
0.45%
流通股本
2.15亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
快而精医药上调2025财年调整后每股收益目标至约2.38美元
投资观察 · 11-05
快而精医药上调2025财年调整后每股收益目标至约2.38美元
快而精医药盘中异动 股价大跌5.30%
市场透视 · 11-05
快而精医药盘中异动 股价大跌5.30%
快而精医药获得美国监管批准,推出高通量Qiastat-Dx Rise系统
投资观察 · 09-02
快而精医药获得美国监管批准,推出高通量Qiastat-Dx Rise系统
快而精医药2025财年第二财季实现净利润96.25百万美元,同比增加152.60%
市场透视 · 08-11
快而精医药2025财年第二财季实现净利润96.25百万美元,同比增加152.60%
美股财报 | 快而精医药发布Q2财报 前半年累计净利润1.87亿美元
同花顺iNews · 08-08
美股财报 | 快而精医药发布Q2财报 前半年累计净利润1.87亿美元
B of A Securities:维持Qiagen(QGEN.US)评级,由买入调整至买入评级, 目标价由50.00美元调整至53.00美元。
金融界 · 06-27
B of A Securities:维持Qiagen(QGEN.US)评级,由买入调整至买入评级, 目标价由50.00美元调整至53.00美元。
Qiagen获巴克莱首次覆盖,给予增持评级, 目标价55.00美元。
金融界 · 06-24
Qiagen获巴克莱首次覆盖,给予增持评级, 目标价55.00美元。
Baird:下调Qiagen(QGEN.US)评级,由优于大市调整至中性评级, 目标价由52.00美元调整至42.00美元。
金融界 · 02-19
Baird:下调Qiagen(QGEN.US)评级,由优于大市调整至中性评级, 目标价由52.00美元调整至42.00美元。
快而精医药2024财年实现净利润83.59百万美元,同比减少75.49%
市场透视 · 02-09
快而精医药2024财年实现净利润83.59百万美元,同比减少75.49%
大摩:下调Qiagen评级
证券之星 · 01-06
大摩:下调Qiagen评级
快而精医药盘中异动 快速上涨5.08%报46.57美元
市场透视 · 2024-12-11
快而精医药盘中异动 快速上涨5.08%报46.57美元
快而精医药2024财年第三财季实现净利润98.06百万美元,同比增加26.01%
市场透视 · 2024-11-16
快而精医药2024财年第三财季实现净利润98.06百万美元,同比增加26.01%
暂无数据
公司概况
公司名称:
快而精医药
所属市场:
NYSE
上市日期:
--
主营业务:
Qiagen N.V.是一家荷兰的控股公司,其子公司是样品检验与化验技术(Sample and Assay Technologies)的主要提供者。该公司是Sample to Insight解决方案的全球领导者,为两个广泛的客户群中的500,000多个客户提供服务:分子诊断(人类保健)和生命科学(学术界,制药研发和工业应用,主要是法医学)。公司在超过100个国家经营其产品。
发行价格:
--
{"stockData":{"symbol":"QGEN","market":"US","secType":"STK","nameCN":"快而精医药","latestPrice":45.22,"timestamp":1765573200000,"preClose":45.44,"halted":0,"volume":977185,"hourTrading":{"tag":"盘前","latestPrice":45.14,"preClose":45.22,"latestTime":"04:43 EST","volume":301,"amount":13586.140679999999,"timestamp":1765791795707},"delay":0,"floatShares":214766878,"shares":216841000,"eps":1.838862,"marketStatus":"盘前交易","change":-0.22,"latestTime":"12-15 07:04:56 EST","open":45.03,"high":45.3,"low":44.82,"amount":44071991.36945,"amplitude":0.010563,"askPrice":45.28,"askSize":610,"bidPrice":45.23,"bidSize":400,"shortable":3,"etf":0,"ttmEps":1.838862,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765809000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":45.22,"dividendRate":0.005529,"preHourTrading":{"tag":"盘前","latestPrice":45.14,"preClose":45.22,"latestTime":"04:43 EST","volume":301,"amount":13586.140679999999,"timestamp":1765791795707},"postHourTrading":{"tag":"盘后","latestPrice":45.25,"preClose":45.22,"latestTime":"16:20 EST","volume":16679,"amount":754538.72,"timestamp":1765574400355},"volumeRatio":0.8263016563727943,"impliedVol":0.3015,"impliedVolPercentile":0.3669},"requestUrl":"/m/hq/s/QGEN/tweets","defaultTab":"tweets","newsList":[{"id":"1165538075","title":"快而精医药上调2025财年调整后每股收益目标至约2.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165538075","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165538075?lang=zh_cn&edition=full","pubTime":"2025-11-05 02:30","pubTimestamp":1762281043,"startTime":"0","endTime":"0","summary":"11月4日电 - 快而精医药公告:*快而精医药第三季度调整后每股收益为0.61美元*快而精医药 - 2025年第三季度净销售额为5.33亿美元,每股收益为0.60美元*快而精医药全年调整后每股收益展望为2.38美元*快而精医药 - 重申2025年全年净销售增长约为4-5%的展望*快而精医药:将2025财年调整后摊薄每股收益目标上调至约2.38美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QGEN","LU1923622614.USD","LU2125909247.SGD","LU2125909593.SGD","LU2433249047.HKD","BK4121"],"gpt_icon":0},{"id":"2581488687","title":"快而精医药盘中异动 股价大跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581488687","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581488687?lang=zh_cn&edition=full","pubTime":"2025-11-05 02:26","pubTimestamp":1762280760,"startTime":"0","endTime":"0","summary":"北京时间2025年11月05日02时26分,快而精医药股票出现异动,股价大幅跳水5.30%。截至发稿,该股报43.26美元/股,成交量138.752万股,换手率0.64%,振幅7.98%。机构评级方面,在所有23家参与评级的机构中,39%的券商给予买入建议,61%的券商给予持有建议,无券商给予卖出建议。快而精医药股票所在的生命科学行业中,整体涨幅为0.39%。快而精近90%的收入来自耗材,其余收入来自仪器仪表和相关服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110502260094ef158a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110502260094ef158a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","LU2125909593.SGD","LU2433249047.HKD","LU2125909247.SGD","QGEN","LU1923622614.USD"],"gpt_icon":0},{"id":"1186975664","title":"快而精医药获得美国监管批准,推出高通量Qiastat-Dx Rise系统","url":"https://stock-news.laohu8.com/highlight/detail?id=1186975664","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186975664?lang=zh_cn&edition=full","pubTime":"2025-09-02 13:45","pubTimestamp":1756791936,"startTime":"0","endTime":"0","summary":"快而精医药(Qiagen NV)宣布,其高通量Qiastat-Dx Rise系统已获得美国监管部门批准,这将扩大患者获得快速综合征检测的机会。\n这一新获批的系统代表着该公司在诊断技术领域的重要进展,能够为医疗机构提供更高效的检测解决方案,进一步提升患者的诊疗体验和医疗服务质量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2433249047.HKD","LU2125909593.SGD","LU2125909247.SGD","LU1923622614.USD","QGEN","BK4121"],"gpt_icon":0},{"id":"2558468121","title":"快而精医药2025财年第二财季实现净利润96.25百万美元,同比增加152.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558468121","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558468121?lang=zh_cn&edition=full","pubTime":"2025-08-11 00:01","pubTimestamp":1754841700,"startTime":"0","endTime":"0","summary":"8月11日,快而精医药公布财报,公告显示公司2025财年第二财季净利润为96.25百万美元,同比增加152.60%;其中营业收入为5.34亿美元,同比增加7.66%,每股基本收益为0.44美元。从资产负债表来看,快而精医药总负债23.18亿美元,其中短期债务5.59亿美元,资产负债比为2.52,流动比率为1.62。机构评级:截至2025年8月11日,当前有19家机构对快而精医药目标价做出预测,其中目标均价为52.13美元,其中最低目标价为43.95美元,最高目标价为61.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000409a6de0849&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000409a6de0849&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QGEN"],"gpt_icon":0},{"id":"2557512118","title":"美股财报 | 快而精医药发布Q2财报 前半年累计净利润1.87亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557512118","media":"同花顺iNews","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557512118?lang=zh_cn&edition=full","pubTime":"2025-08-08 12:00","pubTimestamp":1754625612,"startTime":"0","endTime":"0","summary":"快而精医药发布Q2财报,2025财年前六月累计收入10.17亿美元,去年同期累计收入为9.55亿美元,同比增长6.48%。2025财年前六月累计净利润1.87亿美元,去年同期累计净亏损为1.03亿美元。公司所属行业为生命科学工具和服务。Qiagen N.V.是一家荷兰的控股公司,其子公司是样品检验与化验技术的主要提供者。该公司是Sample to Insight解决方案的全球领导者,为两个广泛的客户群中的500,000多个客户提供服务:分子诊断和生命科学。公司在超过100个国家经营其产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808120609973afe92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808120609973afe92&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QGEN"],"gpt_icon":0},{"id":"2546755846","title":"B of A Securities:维持Qiagen(QGEN.US)评级,由买入调整至买入评级, 目标价由50.00美元调整至53.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2546755846","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546755846?lang=zh_cn&edition=full","pubTime":"2025-06-27 02:06","pubTimestamp":1750961174,"startTime":"0","endTime":"0","summary":"B of A Securities:维持Qiagen(QGEN.US)评级,由买入调整至买入评级, 目标价由50.00美元调整至53.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/27020651332744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["QGEN"],"gpt_icon":0},{"id":"2545990238","title":"Qiagen获巴克莱首次覆盖,给予增持评级, 目标价55.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2545990238","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545990238?lang=zh_cn&edition=full","pubTime":"2025-06-24 21:24","pubTimestamp":1750771475,"startTime":"0","endTime":"0","summary":"Qiagen(QGEN.US)获巴克莱首次覆盖,给予增持评级, 目标价55.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624212729978ce76f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624212729978ce76f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QGEN"],"gpt_icon":0},{"id":"2512174796","title":"Baird:下调Qiagen(QGEN.US)评级,由优于大市调整至中性评级, 目标价由52.00美元调整至42.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512174796","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512174796?lang=zh_cn&edition=full","pubTime":"2025-02-19 18:13","pubTimestamp":1739960009,"startTime":"0","endTime":"0","summary":"Baird:下调Qiagen(QGEN.US)评级,由优于大市调整至中性评级, 目标价由52.00美元调整至42.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19181348262789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["QGEN"],"gpt_icon":0},{"id":"2510051839","title":"快而精医药2024财年实现净利润83.59百万美元,同比减少75.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510051839","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510051839?lang=zh_cn&edition=full","pubTime":"2025-02-09 00:00","pubTimestamp":1739030450,"startTime":"0","endTime":"0","summary":"2月9日,快而精医药公布财报,公告显示公司2024财年净利润为83.59百万美元,同比减少75.49%;其中营业收入为19.78亿美元,同比增加0.66%,每股基本收益为--。从资产负债表来看,快而精医药总负债21.22亿美元,其中短期债务53.48百万美元,资产负债比为2.69,流动比率为3.61。机构评级:截至2025年2月9日,当前有18家机构对快而精医药目标价做出预测,其中目标均价为50.36美元,其中最低目标价为45.00美元,最高目标价为55.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250209000058a23e5b6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250209000058a23e5b6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QGEN"],"gpt_icon":0},{"id":"2501222235","title":"大摩:下调Qiagen评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2501222235","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501222235?lang=zh_cn&edition=full","pubTime":"2025-01-06 20:17","pubTimestamp":1736165833,"startTime":"0","endTime":"0","summary":"大摩:下调Qiagen(QGEN.US)评级,由增持调整至持股观望评级,目标价由50.00美元调整至48.00美元。快而精医药(QGEN.US)公司简介:QIAGEN NV是一家控股公司,致力于提供从样品到洞察的解决方案,使客户能够从包含生命构建块的样品中获得有价值的分子见解。该公司的样品技术从血液、组织和其他材料中分离和处理DNA、RNA和蛋白质。牢固的分析技术使这些生物分子可见并准备好进行分析。它的生物信息学软件和知识库解释数据,以报告相关的、可操作的见解。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106202540aba06b52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106202540aba06b52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QGEN"],"gpt_icon":0},{"id":"2490042168","title":"快而精医药盘中异动 快速上涨5.08%报46.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490042168","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490042168?lang=zh_cn&edition=full","pubTime":"2024-12-11 02:41","pubTimestamp":1733856064,"startTime":"0","endTime":"0","summary":"北京时间2024年12月11日02时41分,快而精医药股票出现波动,股价快速拉升5.08%。截至发稿,该股报46.57美元/股,成交量73.3585万股,换手率0.33%,振幅2.41%。快而精医药股票所在的生命科学行业中,整体涨幅为0.27%。其相关个股中,Inotiv, Inc.、快而精医药、Neogenomics, Inc.涨幅较大,Applied Dna Sciences, Inc.、Inotiv, Inc.、Mainz Biomed N.V.较为活跃,换手率分别为8.30%、6.95%、2.66%,振幅较大的相关个股有Inotiv, Inc.、Applied Dna Sciences, Inc.、Mainz Biomed N.V.,振幅分别为23.03%、16.30%、15.61%。Qiagen 近 90% 的收入来自消耗品,其余收入来自仪器和相关服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211024104984b1841&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211024104984b1841&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QGEN","LU2433249047.HKD","BK4121","LU1923622614.USD","LU2125909247.SGD","LU2125909593.SGD"],"gpt_icon":0},{"id":"2483309434","title":"快而精医药2024财年第三财季实现净利润98.06百万美元,同比增加26.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483309434","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483309434?lang=zh_cn&edition=full","pubTime":"2024-11-16 00:00","pubTimestamp":1731686425,"startTime":"0","endTime":"0","summary":"11月16日,快而精医药公布财报,公告显示公司2024财年第三财季净利润为98.06百万美元,同比增加26.01%;其中营业收入为5.02亿美元,同比增加5.46%,每股基本收益为0.44美元。从资产负债表来看,快而精医药总负债27.40亿美元,其中短期债务5.55亿美元,资产负债比为2.29,流动比率为2.18。机构评级:截至2024年11月16日,当前有18家机构对快而精医药目标价做出预测,其中目标均价为51.47美元,其中最低目标价为45.00美元,最高目标价为60.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000130abc51401&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000130abc51401&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QGEN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.qiagen.com","stockEarnings":[{"period":"1week","weight":-0.0381},{"period":"1month","weight":0.0155},{"period":"3month","weight":-0.0013},{"period":"6month","weight":-0.0401},{"period":"1year","weight":-0.0434},{"period":"ytd","weight":-0.0127}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Qiagen N.V.是一家荷兰的控股公司,其子公司是样品检验与化验技术(Sample and Assay Technologies)的主要提供者。该公司是Sample to Insight解决方案的全球领导者,为两个广泛的客户群中的500,000多个客户提供服务:分子诊断(人类保健)和生命科学(学术界,制药研发和工业应用,主要是法医学)。公司在超过100个国家经营其产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.448276,"avgChangeRate":0.022579},{"month":2,"riseRate":0.62069,"avgChangeRate":0.03033},{"month":3,"riseRate":0.37931,"avgChangeRate":0.010359},{"month":4,"riseRate":0.586207,"avgChangeRate":0.018872},{"month":5,"riseRate":0.517241,"avgChangeRate":0.019555},{"month":6,"riseRate":0.517241,"avgChangeRate":0.004975},{"month":7,"riseRate":0.633333,"avgChangeRate":0.038169},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.005902},{"month":9,"riseRate":0.366667,"avgChangeRate":-0.01054},{"month":10,"riseRate":0.433333,"avgChangeRate":0.017787},{"month":11,"riseRate":0.6,"avgChangeRate":0.034255},{"month":12,"riseRate":0.566667,"avgChangeRate":-0.000191}],"exchange":"NYSE","name":"快而精医药","nameEN":"Qiagen NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"快而精医药(QGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供快而精医药(QGEN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"快而精医药,QGEN,快而精医药股票,快而精医药股票老虎,快而精医药股票老虎国际,快而精医药行情,快而精医药股票行情,快而精医药股价,快而精医药股市,快而精医药股票价格,快而精医药股票交易,快而精医药股票购买,快而精医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"快而精医药(QGEN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供快而精医药(QGEN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}